MCID: ESP027
MIFTS: 45

Esophagus Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Squamous Cell Carcinoma

MalaCards integrated aliases for Esophagus Squamous Cell Carcinoma:

Name: Esophagus Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Esophagus 70
Oesophagus Squamous Cell Carcinoma 12
Esophageal Squamous Cell Carcinoma 44
Scc of Oesophagus 12
Scc of Esophagus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3748
MeSH 44 D000077277
NCIt 50 C4024
SNOMED-CT 67 276804009
UMLS 70 C0279626

Summaries for Esophagus Squamous Cell Carcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial squamous cells located in the esophagus.

MalaCards based summary : Esophagus Squamous Cell Carcinoma, also known as squamous cell carcinoma of esophagus, is related to gastric adenocarcinoma and gastric cardia adenocarcinoma. An important gene associated with Esophagus Squamous Cell Carcinoma is MIR296 (MicroRNA 296), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Irinotecan and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include esophagus, lymph node and lung.

Related Diseases for Esophagus Squamous Cell Carcinoma

Diseases related to Esophagus Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 301)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 31.1 TP53 HOTAIR BANCR
2 gastric cardia adenocarcinoma 30.7 MEG3 HOTAIR
3 retinitis pigmentosa 11 30.7 TP53 MIR296 HOTAIR
4 retinoblastoma 30.6 TP53 MEG3 HOTAIR BANCR
5 esophagus adenocarcinoma 30.4 TP53 AFAP1-AS1
6 thyroid cancer, nonmedullary, 1 30.2 MEG3 HOTAIR BANCR
7 squamous cell carcinoma 30.2 TUG1 TP53 TINCR LINC01233 HOTAIR
8 cholangiocarcinoma 30.1 TUG1 TP53 AFAP1-AS1
9 oral squamous cell carcinoma 30.1 TUG1 TP53 MIR296 MEG3 HOTAIR
10 lung squamous cell carcinoma 29.9 TUG1 TP53 NPTN-IT1 MEG3
11 nasopharyngeal carcinoma 29.8 TP53 NPTN-IT1 MEG3 HOTAIR AFAP1-AS1
12 lung cancer susceptibility 3 29.8 TUG1 TP53 NPTN-IT1 MEG3 HOTAIR AFAP1-AS1
13 kidney cancer 29.7 TP53 MEG3 HOTAIR
14 bladder cancer 29.5 TUG1 TP53 TINCR MEG3 HOTAIR BANCR
15 myeloma, multiple 29.3 TUG1 TP73-AS1 TP53 MEG3 HOTAIR
16 cervical cancer 29.2 TUG1 TP53 NPTN-IT1 MEG3 HOTAIR
17 glioblastoma 29.2 TUG1 TP73-AS1 TP53 MIR296 MEG3 HOTAIR
18 glioma 29.2 TP73-AS1 TP53 MIR296 MEG3 HOTAIR
19 gallbladder cancer 29.1 TUG1 TP53 NPTN-IT1 MEG3 HOTAIR AFAP1-AS1
20 gastric cancer 28.7 TUG1 TP53 TINCR TDRG1 NPTN-IT1 MEG3
21 esophagitis 10.9
22 neutropenia 10.9
23 dysphagia 10.8
24 in situ carcinoma 10.8
25 hypoxia 10.7
26 squamous cell papilloma 10.6
27 papilloma 10.6
28 47,xyy 10.6
29 esophageal disease 10.6
30 body mass index quantitative trait locus 1 10.6
31 barrett esophagus 10.6
32 rapidly involuting congenital hemangioma 10.5
33 thrombocytopenia 10.5
34 gastroesophageal reflux 10.5
35 mucositis 10.5
36 severe combined immunodeficiency 10.5
37 achalasia 10.5
38 pituitary tumors 10.5
39 xeroderma pigmentosum, variant type 10.5
40 48,xyyy 10.5
41 respiratory failure 10.4
42 melanoma 10.4
43 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
44 laurence-moon syndrome 10.4
45 helicobacter pylori infection 10.4
46 exanthem 10.4
47 gastritis 10.4
48 stomatitis 10.4
49 cytokine deficiency 10.4
50 ataxia-telangiectasia 10.4

Graphical network of the top 20 diseases related to Esophagus Squamous Cell Carcinoma:



Diseases related to Esophagus Squamous Cell Carcinoma

Symptoms & Phenotypes for Esophagus Squamous Cell Carcinoma

Drugs & Therapeutics for Esophagus Squamous Cell Carcinoma

Drugs for Esophagus Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
2
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
3
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
4
Trioxsalen Approved Phase 3 3902-71-4 5585
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
6
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
7
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
8
leucovorin Approved Phase 3 58-05-9 6006
9
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
10
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
11
Nedaplatin Approved, Investigational Phase 3 95734-82-0
12
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
13
nivolumab Approved Phase 3 946414-94-4
14
Ipilimumab Approved Phase 3 477202-00-9
15
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Andrographolide Investigational Phase 3 5508-58-7
18 Antirheumatic Agents Phase 3
19 Anti-Inflammatory Agents, Non-Steroidal Phase 3
20 Platelet Aggregation Inhibitors Phase 3
21 Anti-Inflammatory Agents Phase 3
22 Analgesics, Non-Narcotic Phase 3
23 Analgesics Phase 3
24 Fibrinolytic Agents Phase 3
25 Cyclooxygenase Inhibitors Phase 3
26 Antipyretics Phase 3
27 Tea Phase 3
28 Ether Phase 3
29 Dihematoporphyrin Ether Phase 3
30 Photosensitizing Agents Phase 3
31 Hematoporphyrins Phase 3
32 Dermatologic Agents Phase 3
33 Hematoporphyrin Derivative Phase 3
34
Megestrol Phase 3 3562-63-8 19090 3080587
35 Contraceptives, Oral Phase 3
36 Antineoplastic Agents, Hormonal Phase 3
37 Contraceptive Agents Phase 3
38 topoisomerase I inhibitors Phase 3
39 Vitamin B9 Phase 3
40 Folate Phase 3
41 Vitamin B Complex Phase 3
42 Antiparasitic Agents Phase 3
43 Andrographis Phase 3
44 Anti-Infective Agents Phase 3
45 Antiviral Agents Phase 3
46 Antiprotozoal Agents Phase 3
47 Micronutrients Phase 3
48 Antidotes Phase 3
49 Trace Elements Phase 3
50 Nutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 308)
# Name Status NCT ID Phase Drugs
1 Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer Unknown status NCT02607540 Phase 3
2 A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
3 An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
4 Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial Unknown status NCT02604615 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
5 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Unknown status NCT02603159 Phase 3 Capecitabine(Aibin)
6 Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial Unknown status NCT01398449 Phase 3
7 An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas Unknown status NCT02611700 Phase 3 Nimotuzumab;Paclitaxel;Cisplatin;Placebo
8 A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma Unknown status NCT02570893 Phase 3 Paclitaxel and carboplatin
9 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
10 Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma Unknown status NCT02891083 Phase 3 Adjuvant chemotherapy (Paclitaxel and Cisplatin)
11 Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial. Unknown status NCT01496521 Phase 3 Aspirin
12 Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Unknown status NCT02628665 Phase 3 photosensitizer(photofrin)
13 S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Prospective, Randomized, Multi-center Phase-III Study Completed NCT02813967 Phase 3 S-1
14 A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Completed NCT01591135 Phase 3 Paclitaxel plus 5-fluorouracil;Cisplatin plus 5-fluorouracil
15 Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy Completed NCT02644408 Phase 3 Megestrol(Yining)
16 A Prospective, Multicenter, Randomized Controlled Study to Compare Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Completed NCT02399306 Phase 3 Enteral nutrition
17 A Multicenter Randomized, Controlled Phase III Clinical Trial of Pembrolizumab Plus Paclitaxel and Cisplatin Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-002) Recruiting NCT04807673 Phase 3 Paclitaxel;Cisplatin
18 Multicenter Prospective Randomized Controlled Study of Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone in the Treatment of pN1-2 (pT1b-3N1-2M0) Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT04009265 Phase 3
19 Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903) Recruiting NCT04138212 Phase 3 Paclitaxel, Cisplatin
20 The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer Recruiting NCT04196075 Phase 3 Andrographis Paniculata
21 A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) Recruiting NCT04210115 Phase 3 placebo;cisplatin;5-FU;leucovorin;levoleucovorin;oxaliplatin
22 A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1001 in Combination With Fluorouracil and Cisplatin (FP) Compared to Placebo in Combination With FP as First-Line Therapy in Subjects With Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Recruiting NCT04187352 Phase 3 CS1001+ Fluorouracil+Cisplatin;Placebo+ Fluorouracil+Cisplatin
23 A Randomized Controlled Phase III Trial of Comparing Local Field With Additional Prophylactic Irradiation in Chemoradiotherapy for Clinical-T1bN0M0 Esophageal Cancer Recruiting NCT04328948 Phase 3
24 A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15) Recruiting NCT03748134 Phase 3 Placebo;Cisplatin;Paclitaxel;Fluorouracil
25 A Randomized Phase II/III Study of Paclitaxel/Cisplatin Versus Cisplatin/5-fluorouracil in Neoadjuvant Chemoradiation Followed by Surgery for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) Recruiting NCT03623737 Phase 2, Phase 3 neoadjuvant chemoradiation
26 A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT02465736 Phase 3 Docetaxel;Cisplatin;Vinorelbine;Cisplatin
27 A Randomized Phase Ⅱ/Ⅲ Trial of Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03600831 Phase 2, Phase 3 Docetaxel plus cisplatin
28 A Phase III Study of Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma Recruiting NCT03790553 Phase 3
29 NEoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed (NEEDS Trial) Recruiting NCT04460352 Phase 3 Carboplatin, paclitaxel;Carboplatin, paclitaxel;Cisplatin, paclitaxel;Oxaliplatin, calcium folinate, 5-fluorouracil
30 A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) Recruiting NCT04550260 Phase 3 Durvalumab;Placebo;cisplatin + fluorouracil;cisplatin + capecitabine
31 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy Recruiting NCT04543617 Phase 3 Tiragolumab;Atezolizumab;Tiragolumab Matching Placebo;Atezolizumab Matching Placebo
32 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma Recruiting NCT03957590 Phase 3 Tislelizumab;Placebo;Paclitaxel;Cisplatin
33 A Randomized, Double-blind, Multicenter, Phase III Clinical Trial Comparing HLX10 (Recombinant Anti-pd-1 Humanized Monoclonal Antibody Injection) With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Recruiting NCT03958890 Phase 3 HLX10 100 mg in 10 ml Injection;Placebos
34 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Camrelizumab (SHR-1210) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT04426955 Phase 3 Camrelizumab;Paclitaxel;Cisplatin;Placebo
35 Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study Recruiting NCT04415853 Phase 3 Lerotinib;Irinotecan/Tegafur
36 Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Trial Recruiting NCT02461043 Phase 3 paclitaxel; cisplatin
37 A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma Recruiting NCT02409186 Phase 3 Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
38 A Phase III, Randomized Controlled Study of Neo-adjuvant Toripalimab (JS001) in Combination With Chemotherapy Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Recruiting NCT04280822 Phase 3 Neoadjuvant immunochemotherapy
39 Adjuvant Esophagectomy Versus Chemoradiation for Patients With Clinical Stage N0 and Pathological Stage T1b (After Endoscopic Submucosal Dissection, ESD) Esophageal Squamous Cell Carcinoma (Ad-ESD Trial): a Multicentric, Open Label, Randomized Trial Recruiting NCT04135664 Phase 3
40 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT04540211 Phase 3 Atezolizumab;Tiragolumab;Paclitaxel;Cisplatin;Atezolizumab Matching Placebo;Tiragolumab Matching Placebo
41 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel;FOLFOX regimen;CAPOX regimen;Docetaxel;5FU
42 A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy Recruiting NCT03829969 Phase 3
43 A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer Active, not recruiting NCT01137123 Phase 3 adjuvant chemotherapy
44 A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial Active, not recruiting NCT02459457 Phase 3 Paclitaxel and Cisplatin;Paclitaxel and Fluorouracil;Paclitaxel and Carboplatin
45 A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma Active, not recruiting NCT03430843 Phase 3 Tislelizumab;Paclitaxel;Docetaxel;Irinotecan
46 A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Active, not recruiting NCT03783442 Phase 3 Cisplatin;Capecitabine;Paclitaxel;Fluorouracil (5-FU);Oxaliplatin;Tislelizumab;Placebo
47 Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer Active, not recruiting NCT02025036 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
48 Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma; Active, not recruiting NCT01745107 Phase 3
49 A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma Active, not recruiting NCT02395705 Phase 3 cisplatin and paclitaxel
50 A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma Active, not recruiting NCT03143153 Phase 3 Cisplatin;Fluorouracil

Search NIH Clinical Center for Esophagus Squamous Cell Carcinoma

Cochrane evidence based reviews: esophageal squamous cell carcinoma

Genetic Tests for Esophagus Squamous Cell Carcinoma

Anatomical Context for Esophagus Squamous Cell Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagus Squamous Cell Carcinoma:

19
Esophagus

MalaCards organs/tissues related to Esophagus Squamous Cell Carcinoma:

40
Lymph Node, Lung, Liver, Testis, Thyroid, Pituitary, Kidney

Publications for Esophagus Squamous Cell Carcinoma

Articles related to Esophagus Squamous Cell Carcinoma:

(show top 50) (show all 160)
# Title Authors PMID Year
1
The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. 47
20485139 2010
2
HAND2-AS1: A functional cancer-related long non-coding RNA. 61
33556872 2021
3
The First Literature Case Report: Synchronous Squamous Cell Carcinoma of Esophagus and Adenocarcinoma of Gallbladder. 61
33686458 2021
4
A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus. 61
33762694 2021
5
Comparison of treatment response assessed by 18F-FDG PET/CT with the histopathological response using tumor regression grading on surgically resected specimen following neoadjuvant chemotherapy in squamous cell carcinoma of esophagus. 61
33795613 2021
6
Alterations of RNA splicing patterns in esophagus squamous cell carcinoma. 61
33563334 2021
7
The prognostic value of tumor-stromal ratio combined with TNM staging system in esophagus squamous cell carcinoma. 61
33442408 2021
8
Plummer-Vinson syndrome: A decade's experience of 132 cases from a single center. 61
32525241 2021
9
Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma. 61
33408308 2021
10
Long-term (17 years) subjective and objective evaluation of the durability of laparoscopic Heller esophagomyotomy in patients with achalasia of the esophagus (90% of follow-up): a real challenge to POEM. 61
33471177 2021
11
Comparative study on artificial intelligence systems for detecting early esophageal squamous cell carcinoma between narrow-band and white-light imaging. 61
33519142 2021
12
Utility of radial incision and cutting with steroid injection for refractory stricture after endoscopic submucosal dissection for large superficial esophageal squamous cell carcinoma. 61
33398559 2021
13
Modified reverse-puncture anastomotic technique vs. traditional technique for total minimally invasive Ivor-Lewis esophagectomy. 61
33298066 2020
14
Comment on "Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus". 61
33201106 2020
15
Response to Comment on "Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus". 61
33086329 2020
16
Stromal microenvironment promoted infiltration in esophageal adenocarcinoma and squamous cell carcinoma: a multi-cohort gene-based analysis. 61
33122682 2020
17
Proteomic variations of esophageal squamous cell carcinoma revealed by combining RNA-seq proteogenomics and G-PTM search strategy. 61
32913912 2020
18
Clinical profile of patients presenting with dysphagia - an experience from a tertiary care center in North India. 61
32514456 2020
19
Persistent cough: An unexpected diagnosis. 61
32754543 2020
20
Development and validation of a radiomics signature on differentially expressed features of 18F-FDG PET to predict treatment response of concurrent chemoradiotherapy in thoracic esophagus squamous cell carcinoma. 61
32065875 2020
21
Detection of HPV DNA in Esophageal Lesions: a Cross-Sectional Study. 61
32162873 2020
22
Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study. 61
31855875 2019
23
Deubiquitylatinase inhibitor b-AP15 induces c-Myc-Noxa-mediated apoptosis in esophageal squamous cell carcinoma. 61
31342239 2019
24
Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. 61
31619265 2019
25
MicroRNA-148a regulates the MAPK/ERK signaling pathway and suppresses the development of esophagus squamous cell carcinoma via targeting MAP3K9. 61
31378889 2019
26
UGT2B17 and miR-224 contribute to hormone dependency trends in adenocarcinoma and squamous cell carcinoma of esophagus. 61
31164411 2019
27
Long noncoding RNA HAND2-AS1 inhibits cancer cell proliferation, migration, and invasion in esophagus squamous cell carcinoma by regulating microRNA-21. 61
30520131 2019
28
Gastric Conduit Perforation: A Late Fatal Complication after Esophagectomy. 61
31497418 2019
29
REV7 confers radioresistance of esophagus squamous cell carcinoma by recruiting PRDX2. 61
30657231 2019
30
Identifying the differentially expressed microRNAs in esophagus squamous cell carcinoma of Kazakh patients in Xinjiang. 61
30854040 2019
31
Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis. 61
30336280 2018
32
CFTR inhibits the invasion and growth of esophageal cancer cells by inhibiting the expression of NF-κB. 61
30358020 2018
33
Clinic implication of MUC1 O-glycosylation and C1GALT1 in esophagus squamous cell carcinoma. 61
30076562 2018
34
Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis. 61
30461614 2018
35
Considering the downregulation of Tpm1.6 and Tpm1.7 in squamous cell carcinoma of esophagus as a potent biomarker. 61
30259780 2018
36
Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma. 61
29908962 2018
37
Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: A critical review. 61
29548487 2018
38
Expression profiles of Annexin A1, formylated peptide receptors and cyclooxigenase-2 in gastroesophageal inflammations and neoplasias. 61
29254791 2018
39
Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. 61
29713660 2018
40
The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus. 61
29066057 2018
41
Genome-wide screening for genomic aberrations in Kazakh patients with esophageal squamous cell cancer by comparative genomic hybridization. 61
31938128 2018
42
GEJ cancers: gastric or esophageal tumors? searching for the answer according to molecular identity. 61
29262640 2017
43
Endoscopic diagnosis and management of early squamous cell carcinoma of esophagus. 61
28815064 2017
44
A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma. 61
28203424 2017
45
The Prognostic Value of Decreased KLF4 in Digestive System Cancers: A Meta-Analysis from 17 Studies. 61
29062163 2017
46
Genotypes of CYP1A1, SULT1A1 and SULT1A2 and risk of squamous cell carcinoma of esophagus: outcome of a case-control study from Kashmir, India. 61
26455829 2016
47
Multiple Meningocerebral Metastasis and Extensive Skull Metastasis from Squamous Cell Carcinoma of Esophagus: A Case Report and Review of Literature. 61
27867927 2016
48
Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway. 61
26831667 2016
49
Complete response to abdominal bulky lymph node recurrence in an esophageal cancer patient treated with S-1 monotherapy: A case report. 61
27313714 2016
50
MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. 61
26711784 2016

Variations for Esophagus Squamous Cell Carcinoma

Cosmic variations for Esophagus Squamous Cell Carcinoma:

9 (show top 50) (show all 11138)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM142081527 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.1006+2T>A p.? 19:58086172-58086172 6
2 COSM140961271 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.838+2T>A p.? 19:58086172-58086172 6
3 COSM109468109 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.433+2T>A p.? 19:58086172-58086172 6
4 COSM86897778 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.838+2T>A p.? 19:58086172-58086172 6
5 COSM98059731 ZNF831 oesophagus,NS,carcinoma,squamous cell carcinoma c.605T>C p.L202P 20:59191624-59191624 6
6 COSM149923539 ZNF831 oesophagus,NS,carcinoma,squamous cell carcinoma c.605T>C p.L202P 20:59191624-59191624 6
7 COSM88515958 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.938C>G p.S313C 17:82831517-82831517 6
8 COSM88515712 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.668C>G p.S223* 17:82831787-82831787 6
9 COSM138690836 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-31C>G p.? 17:82831517-82831517 6
10 COSM88513307 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.170C>G p.S57* 17:82832285-82832285 6
11 COSM88514972 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.80G>C p.C27S 17:82832375-82832375 6
12 COSM138689938 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-889G>C p.? 17:82832375-82832375 6
13 COSM138689466 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-201C>G p.? 17:82831687-82831687 6
14 COSM138688764 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-799C>G p.? 17:82832285-82832285 6
15 COSM88514017 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.777C>A p.Y259* 17:82831678-82831678 6
16 COSM88515841 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.37C>A p.H13N 17:82832418-82832418 6
17 COSM138689254 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-192C>A p.? 17:82831678-82831678 6
18 COSM88514274 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.768C>G p.Y256* 17:82831687-82831687 6
19 COSM138690667 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-301C>G p.? 17:82831787-82831787 6
20 COSM138690762 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-932C>A p.? 17:82832418-82832418 6
21 COSM90465117 ZNF548 oesophagus,NS,carcinoma,squamous cell carcinoma c.1016A>C p.H339P 19:57399267-57399267 6
22 COSM93683971 ZNF548 oesophagus,NS,carcinoma,squamous cell carcinoma c.980A>C p.H327P 19:57399267-57399267 6
23 COSM102366084 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 10:62376905-62376905 6
24 COSM102372996 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 10:62376905-62376905 6
25 COSM104733716 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 10:62376905-62376905 6
26 COSM109217250 ZNF230 oesophagus,NS,carcinoma,squamous cell carcinoma c.87G>C p.Q29H 19:44008861-44008861 6
27 COSM139548867 ZNF230 oesophagus,NS,carcinoma,squamous cell carcinoma c.87G>C p.Q29H 19:44008861-44008861 6
28 COSM100770466 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1117C>T p.R373W 17:32369340-32369340 6
29 COSM100755139 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1210C>T p.R404W 17:32369340-32369340 6
30 COSM90696431 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1219C>T p.R407W 17:32369340-32369340 6
31 COSM139216379 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1210C>T p.R404W 17:32369340-32369340 6
32 COSM91133838 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1162C>T p.R388W 17:32369340-32369340 6
33 COSM131330822 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 6
34 COSM94832002 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 6
35 COSM88860826 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 6
36 COSM88887411 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.86A>T p.E29V 23:152919042-152919042 6
37 COSM89189081 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.71A>T p.E24V 23:152919042-152919042 6
38 COSM94818098 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 6
39 COSM129903764 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 6
40 COSM112129853 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 6
41 COSM125164549 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9439C>T p.P3147S 8:76863231-76863231 6
42 COSM125167660 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6188C>A p.P2063H 8:76853187-76853187 6
43 COSM127363671 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.2120C>G p.S707C 8:76706208-76706208 6
44 COSM127389059 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.10574C>T p.S3525F 8:76864288-76864288 6
45 COSM127376736 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.4099G>A p.D1367N 8:76851020-76851020 6
46 COSM127405081 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.439G>T p.E147* 8:76704527-76704527 6
47 COSM125134824 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6767G>A p.R2256Q 8:76853766-76853766 6
48 COSM127390973 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9517C>T p.P3173S 8:76863231-76863231 6
49 COSM127363056 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6845G>A p.R2282Q 8:76853766-76853766 6
50 COSM125162303 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.10496C>T p.S3499F 8:76864288-76864288 6

Expression for Esophagus Squamous Cell Carcinoma

Search GEO for disease gene expression data for Esophagus Squamous Cell Carcinoma.

Pathways for Esophagus Squamous Cell Carcinoma

Pathways related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.88 TP53 MEG3 HOTAIR

GO Terms for Esophagus Squamous Cell Carcinoma

Sources for Esophagus Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....